Corona Virus Infection
Conditions
Keywords
Antiviral, Virucidal, Nitric Oxide
Brief summary
This is a multi-center, randomized, controlled, phase II clinical efficacy study evaluating a novel Nitric Oxide Releasing Solution (NORS) treatment for the prevention and treatment of COVID-19 in healthcare workers at risk of infection. Participants will be enrolled into one of two components of this study. Based on initial swabs/symptoms, volunteers who are COVID-19 negative will be enrolled in the Prevention study and randomized to receive standard institutional precautions or standard institutional precautions + NORS. Those who are COVID-19 positive will be enrolled in the open-label Treatment Sub-Study.
Detailed description
The novel, human-infecting corona-virus, provisionally named 2019 novel corona virus (2019-nCoV) is a single-strand, positive-sense RNA virus and has a similar receptor-binding domain structure to that of SARS-CoV and MERS-CoV. The virus is transmitted via airborne droplets to the nasal mucosa. Replication occurs locally in the nasal mucosa, in ciliated epithelial cells, over a 3-day incubation period. The mucosal cells are damaged with a resultant inflammatory response similar to the common cold. During this time the virus is shed in nasal secretions causing disease in the lower respiratory tract, potentially causing fatal viral pneumonia. The literature supports that NO or its derivatives have inhibitory effects on a variety of viral infections. This inhibitory effect was shown to be marked in Interferon (IFN) mediated inhibition manifested by activated macrophage. It was also shown to be correlated with s-nitrosylation of viral proteins such as reductases and proteases. Based on the genetic similarities between SARS and corona viruses, similar viricidal effects of NO on COVID-19 can be hypothesized. SaNOtize has developed an innovative approach to provide nitric oxide gas using a formulation called Nitric Oxide Releasing Solution (NORS). This patented solution releases virucidal doses of NO for a sustained period and is effective at rapidly inactivating Influenza A and SARS-CoV-2. NORS delivered as a gargle (AM), nasal spray (PRN) or as a nasopharyngeal flush (PM) has the potential to decontaminate the upper respiratory tract that could preventing transmission and progression of COVID-19 in Healthcare Workers & Individuals at Risk of Infection. The randomized Prevention study will investigate the ability of NORS to prevent COVID-19 infection when used prophylactically. The open-label Treatment Sub-Study is expected to be small and will provide pilot data on the possibility of NORS as a treatment for Mild/Moderate COVID-19 infection.
Interventions
DRUGNORS (Nitric Oxide Releasing Solution)
NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.
Sponsors
The Emmes Company, LLC
Keyrus Life Science
Sanotize Research and Development corp.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)
Intervention model description
Multi-center, prospective, randomized, controlled, phase II, parallel group
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Prevention Study Inclusion Criteria: 1. Capable of understanding and providing signed informed consent and ability to adhere to the requirements and restrictions of this protocol; 2. Men and Women ≥ 19 years of age unless local laws dictate otherwise; 3. English speaking; 4. Must be willing to use an adequate form of contraception (or abstinence) from the time of the first dose with the IMP until after the last dose of IMP. 5. Be symptom-free at screening/baseline. 6. Work/live in contact with COVID-19 infected patients or scheduled to work in a setting with high likelihood of contact with COVID-19 infected patients. Prevention Study
Exclusion criteria
1. Prior Tracheostomy; 2. Concomitant treatment of respiratory support (involving any form of oxygen therapy); 3. Any clinical contraindications, as judged by the attending physician; 4. Any symptoms consistent with COVID-19; 5. Pregnant; 6. Mentally or neurologically disabled patients who are considered not fit to consent to their participation in the study; 7. Prior COVID-19 infection. Treatment Sub study Inclusion Criteria: 1. Capable of understanding and providing signed informed consent and ability to adhere to the requirements and restrictions of this protocol; 2. Men and Women ≥ 19 years of age unless local laws dictate otherwise; 3. English speaking; 4. Must be willing to use an adequate form of contraception (or abstinence) from the time of the first dose with the IMP until after the last dose of IMP; 5. Positive COVID-19 test or presentation of clinical symptoms defined as fatigue with either fever \>37.2 (oral) and/or a persistent cough. Treatment Sub Study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevention Study: Measure the effect of NORS on the prevention of COVID-19 infection among health care professionals at risk of exposure to COVID-19 | 14 days | Measure the proportion of subjects with either swab positive COVID-19 or presentation of clinical symptoms as measured by fatigue with either fever \>37.2 (oral)and/or a persistent cough. |
| Treatment Sub Study: Measure the efficacy of NORS at reducing the progression of COVID- 19 | 21 days | Measure the proportion of participants requiring requiring hospitalization for COVID-19/flu-like symptoms and/or needing oxygen therapy, BIPAP/CPAP, intubation and mechanical ventilation following enrollment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Treatment Sub Study: Measure the virucidal effect of NORS Treatments | 21 days | Measure the median number of days to negative conversion of SARS-CoV-2 RT-PCR from a nasopharyngeal swabs. |
| Treatment Sub Study: Determine effect of NORS on the speed of clinical recovery | 21 days | Determine the time to clinical recovery in participants with COVID-19 by measuring the median number of days from enrollment to discharge (if admitted), or to normalization of fever (defined as \<36.6°C from axillary site, or \< 37.2°C from oral site or \< 37.8°C from rectal or tympanic site), respiratory rate (\< 24 bpm while breathing room air). |
| Prevention Study: Measure the effect of NORS on the prevention of progression of COVID- 19 | 21 days | Measure the proportion of participants requiring requiring hospitalization for COVID-19/flu-like symptoms and/or needing oxygen therapy, BIPAP/CPAP, intubation and mechanical ventilation following enrollment. |
| Treatment & Sub Study: Determine positive sero-conversion for SARS-CoV-2 | 21 days | Measure the proportion of participants that have a positive sero-conversion for SARS-CoV-2 |
| Treatment Sub Study: Determine the reduction in clinical symptoms | 21 days | Measure the reduction clinical symptoms in participants with COVID- 19 by the magnitude of the change in Modified Jackson Cold Score Diary Score (5-unit change is a substantial clinical benefit). |
| Prevention Study: Measure the tolerability of NORS treatments | 21 days | Measure the tolerability of the NORS treatments as determined by number of adverse events, pain, discomfort or discontinuations of treatment. |
Countries
Canada
Outcome results
None listed